Announcer:
Welcome to CME on ReachMD. This episode is part of our MinuteCE curriculum.

Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives. 

Dr. McDaniel: 
This is CME on ReachMD. I'm Dr. Jenny McDaniel, and I'm joined today by Dr. Stephanie Ambrose. Dr. Ambrose, with all of these new therapies for hemophilia, including new and novel mechanisms, what are some considerations for collaborating as part of a multidisciplinary team when treating patients with these therapies?

Dr. Ambrose:
Yeah. So taking care of patients with hemophilia, it's so important to have them treated with a multidisciplinary team. Having a multidisciplinary approach is so very important.

So when thinking about some of these newer therapies, site preparation is very important. So assigning a team lead for therapy implementation, whether that is the nurse navigator, the physician, the advanced practice provider, whoever, they need to have someone that is lead point in having these discussions for therapy implementation. We have to develop detailed plans with target dates and responsibilities. Staff education is so vastly important. So utilizing checklists and protocols to educate nursing, social work, and other team members to continue to provide ongoing training and resources as things change. Patient coordination is very important. So it's important to obtain informed consent from the patient and to ensure that they understand what the process is for the treatments that we're discussing. What are the potential complications? What does the follow-up look like? Establish clear communication channels for patient education and support, implementing consistent lab test methods and ensure that you're getting reliable results. Resource utilization, so leveraging manufacturer support programs to help with the initial setup and the ongoing assistance. They can often be very helpful in helping to obtain access to some of these therapies. Exploring options for local lab services and mobile phlebotomy to help reduce patient burden, in terms of the monitoring that may be needed. All of these are things that should be taken into consideration.

Dr. McDaniel, do you have anything to add?

Dr. McDaniel: 
Thanks so much for that overview, Dr. Ambrose.

For these new therapies, there will be ongoing monitoring and support, and we know we still have a lot to learn about these new therapies, and this will be essential to ensure that we achieve optimal patient outcomes during therapy. So utilizing all the available resources and the vast knowledge that we all are generating with the implementation of these therapies.

It's also important that we foster and continue to encourage collaboration among all stakeholders to help streamline the implementation process and enhance the quality of care for our patients. We want to always maintain an open dialog among our multidisciplinary team to address any evolving changes and share best practices. And we also want to include our patients in that open dialog as well and hear more from these lived experience experts as we navigate this new landscape.

Well, this has been a great bite-sized discussion. Make sure to tune in to the rest of our microlearning activities in this series for more information. Thank you.

Announcer:
You have been listening to CME on ReachMD.  This activity is provided by The France Foundation and is part of our MinuteCE curriculum.

To receive your free CME credit, or to download this activity, go to ReachMD.com/CME. Thank you for listening.